Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
Date:8/9/2011

EAST NORRITON, Pa., Aug. 9, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011.

"This is an important time for Tengion as we continue to make progress on our lead clinical and preclinical programs, as well as on our corporate and partnership strategy," said David Scheer, chairman of the Tengion board of directors. "Our search for a new chief executive officer is underway and our dialogue with the FDA is ongoing as we continue to advance our Neo-Urinary Conduit clinical trial. We expect to provide more updates in the near term as we execute on our overall strategy."

Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag.  Patients requiring some form of urinary diversion with today's standard of care, the use of a segment of bowel tissue to construct a conduit for urine to exit from the body into an ostomy bag, are at risk of complications associated with the use of bowel tissue as well as those associated with the surgery to harvest the bowel tissue.

The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach f
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tengion Announces Leadership Transition
2. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
3. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
4. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
5. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
6. Tengion Announces Pricing of $31.4 Million Private Placement
7. Tengion Addresses Recent Trading Activity in its Common Stock
8. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
10. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
11. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
(Date:9/16/2014)... East Longmeadow, MA (PRWEB) September 16, 2014 ... the appointment of Brian Highley as CEO of CIRTEC. ... at this exciting point for the Company.” noted Brian ... and operational performance while sustaining strong organic growth over ... accelerate CIRTEC’s growth by continuing to improve and expand ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... September 16, 2014 Convoy Therapeutics, ... and effective products to treat patients directly at ... a proprietary SPACE™ Technology Platform announced today that ... will present at the White Hat Life Science ... Hyatt Regency Phoenix. In addition, interested individuals ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... 19, 2012 RayBiotech, Inc. today announced that it ... core facilities at academic and government research institutes in ... the partnership program, core diagnostics facilities will be able ... component of their current services offerings at no cost ...
... 19, 2012  New data presented today studied the ... nitric oxide (NO) to patients being evaluated for ... privately held, advanced development-stage technology company, announced that ... Right Heart Catheterization (RHC) in subjects being evaluated ...
... Childhood obesity is a widespread global epidemic ... (NAFLD) [2] is now the leading cause of liver ... Liver Congress™ 2012 furthers this concern by showing that childhood ... the most common form of liver cancer [3] - ...
Cached Biology Technology:RayBiotech, Inc. Announces New Diagnostic Core Facility Partnering Program 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 2Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 3Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood 4
(Date:9/16/2014)... The fire is human-caused and is still under ... and is mostly being fueled by grass and timber. ... to higher humidity. Yesterday (8/15), firefighters made progress ... fireline on the West and North sides of the fire. ... 7 20-person Crews, 4 Hot Shot Crews, 1 large Type ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
(Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... Humans and animals are able to perceive even the ... channels play a crucial role in the mediation of ... membrane which are highly responsive to external signals. Mechanosensitive ... ions (electrically charged particles), to cross the cell membrane, ...
... oil and gas concessions threatens the megadiverse Peruvian Amazon. ... reach around 70% of the region, threatening biodiversity and ... from a pair of researchers from the Institut de ... Barcelona (UAB), and the Washington DC-based NGO Save America,s ...
... and THE HAGUE, The Netherlands -- Recognizing the ... relationship and become recognized research leaders in the ... security, Stevens Institute of Technology recently entered into ... A Memorandum of Understanding (MOU) between the university ...
Cached Biology News:MDC researchers link protein tether to touch perception 2A second hydrocarbon boom threatens the Peruvian Amazon 2A second hydrocarbon boom threatens the Peruvian Amazon 3Stevens and TNO to collaborate on maritime security 2
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... against Nonmuscle Myosin II Heavy Chain ... in TBS + 0.03% Thimerosal) This ... SDVNETQPPQSE corresponding to the C-terminus of ... (MHC-B) This antibody is effective in ...
... reduced and non-reduced forms. It does not react ... XII. Factor XIII is a Beta-globulin found in ... XIII-A is the catalytic subunit and is a ... in plasma as an Alpha2Beta2 heterodimer (M.W. 320kDa); ...
... is a fully integrated system for fluorescent ... that deliver excellent quality microarray images. The ... microarray scanner that is based on patented ... rejection and spatial resolution. The DNAscope V ...
Biology Products: